These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28025383)

  • 1. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation.
    Rozen-Zvi B; Schneider S; Lichtenberg S; Green H; Cohen O; Gafter U; Chagnac A; Mor E; Rahamimov R
    Nephrol Dial Transplant; 2017 Feb; 32(2):393-399. PubMed ID: 28025383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation.
    Rahamimov R; Tifti-Orbach H; Zingerman B; Green H; Schneider S; Chagnac A; Mor E; Fox BD; Rozen-Zvi B
    Eur J Clin Pharmacol; 2019 Jul; 75(7):951-958. PubMed ID: 30762079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation.
    O'Regan JA; Canney M; Connaughton DM; O'Kelly P; Williams Y; Collier G; deFreitas DG; O'Seaghdha CM; Conlon PJ
    J Nephrol; 2016 Apr; 29(2):269-276. PubMed ID: 26374111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure.
    Sapir-Pichhadze R; Wang Y; Famure O; Li Y; Kim SJ
    Kidney Int; 2014 Jun; 85(6):1404-11. PubMed ID: 24336032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
    Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
    Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
    Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
    Front Immunol; 2021; 12():746013. PubMed ID: 34659243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
    Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
    Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival.
    Gallagher HM; Sarwar G; Tse T; Sladden TM; Hii E; Yerkovich ST; Hopkins PM; Chambers DC
    J Heart Lung Transplant; 2015 Nov; 34(11):1442-8. PubMed ID: 26186804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children.
    Pollock-Barziv SM; Finkelstein Y; Manlhiot C; Dipchand AI; Hebert D; Ng VL; Solomon M; McCrindle BW; Grant D
    Pediatr Transplant; 2010 Dec; 14(8):968-75. PubMed ID: 21040278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
    Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
    Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High tacrolimus intra-patient variability is associated with graft rejection, and
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
    World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation.
    Shuker N; Shuker L; van Rosmalen J; Roodnat JI; Borra LC; Weimar W; Hesselink DA; van Gelder T
    Transpl Int; 2016 Nov; 29(11):1158-1167. PubMed ID: 27188932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
    Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
    Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation.
    van Gelder T
    Kidney Int; 2014 Jun; 85(6):1267-8. PubMed ID: 24875549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.